<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922908</url>
  </required_header>
  <id_info>
    <org_study_id>SAMCIS</org_study_id>
    <nct_id>NCT01922908</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stromal Cells for Ischemic Stroke</brief_title>
  <acronym>SAMCIS</acronym>
  <official_title>SAfety of Mesenchymal Stromal Cells for Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sean Savitz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if mesenchymal stem cells given by IV is feasible
      and safe in patients with recent ischemic stroke and to decide the maximum tolerated dose
      when given between 3-10 days after an ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo controlled study. . Approximately 48 subjects
      will be enrolled in the trial, undergo a real or SHAM MSC IV infusion and will be follow out
      to 1 year. There will potentially be 4 Cohorts with the dose escalation at a 3:1
      randomization schedule

      Objectives:

        -  The primary hypothesis' are that intravenous administration of allogeneic bone marrow
           derived mesenchymal stem cells is feasible and safe in patients with recent ischemic
           stroke and to determine the maximum tolerated dose (MTD) of IV MSCs when administered
           sub-acutely between 3-10 days following ischemic stroke.

        -  The secondary hypothesis is that allogeneic MSC transplantation will improve functional
           outcome after recent ischemic stroke.

      Safety and clinical efficacy points to be evaluated at Day 7 clinic visit, Day 30, Day 60,
      Day 90, and Day 180. Primary outcome or Primary endpoint of the study is to define the safety
      or harm of the MSCs
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Plan to change the trial design
  </why_stopped>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD) of IV MSCs</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved functional outcome</measure>
    <time_frame>1 year</time_frame>
    <description>as assessed by changes in mRS, NIHSS, Fugyl-Meyer and Barthel Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>MSC infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHAM infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of normal saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC Infusion</intervention_name>
    <description>Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset</description>
    <arm_group_label>MSC infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>SHAM infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. acute ischemic stroke

          2. age 18 to 83 years

          3. post stroke mRS &gt; 3

          4. NIHSS of 7-25

          5. Deficits on the total NIHSS can be lower than 7 provided the patients have moderate
             aphasia or visual loss (2 on the Best Language or Visual loss NIHSS subcomponent)
             *Criteria for mRS not used for this category of subjects

          6. Last seen normal st within 3-9 days prior to stroke. Time of onset for wake-up stroke
             will be defined as the time the patient woke up with symptoms.

          7. stem cell transplantation procedure must be performed between 3-10 days after stroke
             symptom onset

        Exclusion Criteria:

          1. Ischemic stroke, primary hemorrhagic or traumatic lesion of the brain or myocardial
             infarction within past 30 days prior to current stroke.

          2. Mechanical heart valve

          3. Uncontrolled seizure disorder, defined as a seizure within the last 6 months

          4. Developmental delay

          5. Chronic kidney disease

          6. Hepatic disease or altered liver function

          7. Pulmonary disease

          8. Cancer within 5 years prior to study

          9. Prior immunosuppression, including chemotherapy within last 3 years

         10. Known HIV

         11. Uncorrected coagulopathy or severe anemia

         12. Pregnancy

         13. Unable to undergo MRI or CT scan

         14. Imaging shows clinically significant hemorrhage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>83 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Savitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Sean Savitz</investigator_full_name>
    <investigator_title>Professor, Department of Neurology, Director, Stroke Program</investigator_title>
  </responsible_party>
  <keyword>Ischemic</keyword>
  <keyword>Stroke</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>MSC</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Bone Marrow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

